Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
tildrakizumab (MK-3222) 是一种高亲和力、选择性抗 IL23p19 单克隆抗体，对中重度银屑病患者细胞色素 P450 代谢的影响
期刊:British Journal of Clinical Pharmacology
影响因子:3
doi:10.1111/bcp.13670
Khalilieh Sauzanne, Hussain Azher, Montgomery Diana, Levine Vanessa, Shaw Peter M, Bodrug Inga, Mekokishvili Lally, Bailey-Smith Candice, Glasgow Xiaoli S, Cheng Amy, Martinho Monika, Iwamoto Marian
